TEM vs RXRX
TEM and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | TEMTempus AI, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $7.70M | — |
| P/B | 0.02 | — |
| P/S | 0.0x | — |
| Revenue | $1.43B(TTM) | — |
| Revenue growth (YoY) | 83.4% | 26.9% |
| Net income | -$254.40M(TTM) | — |
| Earnings growth (YoY) | 65.3% | -39.1% |
| EPS, diluted | $-1.44(TTM) | — |
| EBIT margin | -19.9% | -867.9% |
| ROE | -55.1% | -62.9% |
| ROIC | — | -174.7% |
| 1y total return | -23.9% | -49.7% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: TEM vs RXRX
| 지표 | TEM | RXRX |
|---|---|---|
| 최종 가치 | $10.7K | $3.2K |
| 총수익률 | +6.6% | -67.8% |
| CAGR | +3.0% | -41.3% |
| 변동성 | 97.0% | 83.2% |
| 샤프 | 0.46 | -0.28 |
| 소르티노 | 0.73 | -0.43 |
| 최대 낙폭 | -59.8% | -73.9% |
공통 거래일 533일 기준, 2024-06-14 → 2026-07-31 · 무위험수익률 3.82% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)